Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

3.85
-0.2200-5.41%
Post-market: 4.100.2500+6.49%18:03 EDT
Volume:151.97K
Turnover:613.20K
Market Cap:33.26M
PE:-0.31
High:4.17
Open:4.09
Low:3.85
Close:4.07
Loading ...

Karyopharm Therapeutics Inc : Leerink Partners Cuts Target Price to $8 From $26

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
13 May

RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating

MT Newswires Live
·
13 May

Karyopharm price target adjusted to $10 from $5 at Barclays

TIPRANKS
·
13 May

Karyopharm Therapeutics Inc : RBC Cuts Target Price to $33 From $43

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Karyopharm Therapeutics Q1 EPS $(2.77) Beats $(4.16) Estimate, Sales $30.02M Miss $35.24M Estimate

Benzinga
·
13 May

BRIEF-Karyopharm Therapeutics Q1 Net Income USD -23.462 Million

Reuters
·
13 May

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis That Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Reaffirms 2025 Revenue Guidance of $140-$155 Million

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Phase 3 Sentry Trial Passes Futility Analysis, 80% Enrolled

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc - Exploring Alternatives to Extend Cash Runway

THOMSON REUTERS
·
13 May

Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Reuters
·
10 May

Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Reuters
·
02 May

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

TIPRANKS
·
19 Mar

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Mar